Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
CHR-2797 · 1 trial · 1 indication
| Name | Type | Description |
|---|---|---|
| CHR-2797 (tosedostat) | DRUG | Drug was given orally, once daily, ensuring a dosing interval of approximately 24 hours. Dose escalations took place starting at 10mg and escalating (per protocol) as follows: 20, 40, 90, 130, 180, 240 and 320 mg |
Inclusion Criteria: * Signed, informed consent * Histological or cytologically confirmed malignant solid tumour refractory to standard therapy or for which no standard therapy exists * Evaluable disease * Recovered from the acute adverse effects of prior therapies (excluding alopecia and grade 1 ne...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Merck & Co., Inc. | MRK | 2 | PHASE2 | pembrolizumab |
| Incyte Corporation | INCY | 1 | PHASE2 | Chemotherapy, Retifanlimab |
| Iovance Biotherapeutics Inc | IOVA | 2 | PHASE2 | E7 TCR-T cells, Aldesleukin |
| Novartis AG Sponsored ADR | NVS | 1 | PHASE1 | KFA115, pembrolizumab |
| AstraZeneca PLC | AZN | 1 | - | Trastuzumab deruxtecan |
CHR-2797 is an investigational small molecule being studied for the treatment of advanced solid tumors. It is currently in Phase 1 clinical development and has not been approved by regulatory authorities. The drug is being evaluated in patients with advanced solid tumors to assess its safety and potential therapeutic effects.
CHR-2797 is being developed by United Therapeutics Corporation, a biotechnology company traded on the NASDAQ under the ticker symbol UTHR. The company is conducting clinical research on this investigational oncology drug for the treatment of advanced solid tumors.
CHR-2797 is in Phase 1 clinical development. It is an investigational drug for advanced solid tumors and has not yet received regulatory approval. The Phase 1 trial has been completed, and the drug remains in early-stage clinical investigation.
CHR-2797 has been studied in one clinical trial, identified as NCT00692354, titled "Safety Study to Evaluate CHR-2797 in Patients With Advanced Tumours." This Phase 1 study enrolled 41 participants with advanced solid tumors and has been completed. The trial was uncontrolled and not randomized or double-blinded.
CHR-2797 is not FDA approved. It is an investigational drug currently in Phase 1 clinical development for advanced solid tumors. The completed Phase 1 trial assessed safety, but the drug has not yet received marketing approval from the FDA or other regulatory agencies.